166 related articles for article (PubMed ID: 26546899)
1. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
Alsahebfosoul F; Zavaran Hosseini A; Salehi R; Etemadifar M; Esmaeil N; Jamshidian A
Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):298-305. PubMed ID: 26546899
[TBL] [Abstract][Full Text] [Related]
2. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients.
Chen C; Liang J; Yao G; Chen H; Shi B; Zhang Z; Zhao C; Zhang H; Sun L
Int Immunopharmacol; 2017 Mar; 44():234-241. PubMed ID: 28129605
[TBL] [Abstract][Full Text] [Related]
4. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
[TBL] [Abstract][Full Text] [Related]
5. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.
Bjerg L; Brosbøl-Ravnborg A; Tørring C; Dige A; Bundgaard B; Petersen T; Höllsberg P
J Neuroimmunol; 2012 Aug; 249(1-2):76-82. PubMed ID: 22608884
[TBL] [Abstract][Full Text] [Related]
6. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
[TBL] [Abstract][Full Text] [Related]
7. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
[TBL] [Abstract][Full Text] [Related]
8. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
9. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
[TBL] [Abstract][Full Text] [Related]
13. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
14. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis.
Rizzo R; Bortolotti D; Fredj NB; Rotola A; Cura F; Castellazzi M; Tamborino C; Seraceni S; Baldi E; Melchiorri L; Tola MR; Granieri E; Baricordi OR; Fainardi E
Hum Immunol; 2012 Nov; 73(11):1140-6. PubMed ID: 22922127
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen-G and regulatory T cells during specific immunotherapy for pollen allergy.
Sørensen AE; Johnsen CR; Dalgaard LT; Würtzen PA; Kristensen B; Larsen MH; Ullum H; Søes-Petersen U; Hviid TV
Int Arch Allergy Immunol; 2013; 162(3):237-52. PubMed ID: 24022071
[TBL] [Abstract][Full Text] [Related]
16. Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.
Minagar A; Adamashvili I; Kelley RE; Gonzalez-Toledo E; McLarty J; Smith SJ
J Neuroinflammation; 2007 Jul; 4():16. PubMed ID: 17601341
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
[TBL] [Abstract][Full Text] [Related]
18. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
[TBL] [Abstract][Full Text] [Related]
20. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
